Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16502 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Kevin Cowart und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of South Florida, Tampa, Florida, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Glycated Hemoglobin, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Basal insulin and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are available in two fixed‐ratio combinations (FRCs) for the treatment of type 2 diabetes (T2D), insulin degludec with liraglutide and insulin glargine with lixisenatide. FRCs offer a convenient strategy to administer basal insulin and a GLP‐1 RA, taking advantage of complementary mechanisms in a single injection to minimize treatment burden and improve glycemic control while mitigating weight gain. For most, a glycated haemoglobin (HbA1c) goal for patients with T2D using a FRC would be
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of South Florida, Tampa, Florida, USA.
ORCID-Profile: Kevin Cowart, Nicholas W Carris
Zitieren
APA
Cowart, K., & Carris, N. W. (2025). Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16502
Vancouver
Cowart K, Carris NW. Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16502
BibTeX
@article{Cowart2025,
author = {Cowart, Kevin and Carris, Nicholas W},
title = {Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16502}
}
EUVIMED